SINTX Technologies — Third Quarter 2026 Earnings Summary

Financial Performance:

• Total revenue for the three months ended September 30, 2026, increased more than tenfold to approximately $2.2 million, compared to $208,000 in the prior-year period.
• Gross profit increased to approximately $1.4 million from $93,000 in the prior-year quarter, with gross margin expanding to approximately 62% from 45%.
• Total operating expenses decreased 13% to $3.0 million, down from $3.4 million in the third quarter of 2025.
• Net loss decreased 55% to approximately $1.6 million, compared to $3.5 million during the prior-year quarter.
• Operating loss decreased 51% to $1.6 million, compared with $3.4 million in the third quarter of 2025.
• For the nine months ended September 30, 2026, total revenue increased 315% to approximately $3.0 million.
• SINTX ended the third quarter with approximately $2.0 million in cash and cash equivalents.
• Debt increased to $55,000 as of September 30, 2026, from $7,000 as of December 31, 2025.
• Total stockholders' equity increased to $3.39 million as of September 30, 2026, from $2.93 million as of December 31, 2025.

Guidance and Future Outlook:

• Management expressed confidence that SINTX is well-positioned to pursue additional growth opportunities in 2027.
• Large-animal in vivo studies evaluating silicon nitride-treated medical textiles are expected to be completed in the first quarter of 2027 to support preclinical development of wound care applications.
• The Company continues to pursue revenue growth, operating efficiencies, and additional financing alternatives to support operations and commercialization activities.

Business Segments and Product Lines:

• The Company completed the limited-use release of the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026.
• Initial commercial sales of the SiNAPTIC® Foot & Ankle Osteotomy Wedge System are underway, establishing a foundation for expanding presence in the orthopedic implant market.
• The Company is evaluating opportunities to leverage proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications.
• The industrial business is providing a commercial foundation while the Company pursues healthcare opportunities.
• The Company operates under ISO 13485:2016 and AS9100D quality management systems.

Market and Competitive Landscape:

• The Company sponsored a silicon nitride masterclass with leading orthopedics experts to educate surgeons, develop sales channels, and build a disciplined commercial foundation.
• The Company has 20 years of experience innovating silicon nitride technologies.
• Product portfolio includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, OEM manufacturing of FDA-cleared spinal implants, and the SiNERGY™ technology platform for biocomposite and 3D printing applications.

Risks and Challenges:

• Forward-looking statements highlight risks including the timing and volume of customer orders and product shipments.
• Risks include customer concentration and the potential loss or reduction of business from significant customers.
• Challenges include the Company's ability to maintain or improve manufacturing efficiencies, pricing, and gross margins.
• Uncertainties exist regarding the timing, completion, and results of preclinical studies.
• Risks include the Company's ability to secure licensing partnerships, obtain regulatory clearances or approvals, protect intellectual property, manufacture products at commercial scale, obtain sufficient funding, and achieve market acceptance.
• The Company faces the risk of continuing as a going concern.

Management Commentary and Tone:

• CEO Eric Olson stated that the third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies.
• Management noted that the substantial increase in quarterly revenue and improvements in gross profit and operating performance demonstrate the potential of their advanced manufacturing platform.
• Olson concluded that performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company.

Other Key Points:

• SINTX regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• The Company received aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants at $2.14 per share following a post-quarter-end call triggered by achieving the third-quarter revenue milestone of $2 million.
• The Company will host a conference call and webcast on November 5, 2026, at 4:30 p.m. ET with CEO Eric Olson and CFO Kevin Trask.
• Inventories increased to $2.555 million as of September 30, 2026, from $825,000 as of December 31, 2025.
• Accounts payable increased to $961,000 as of September 30, 2026, from $382,000 as of December 31, 2025.